(0.09%) 5 474.11 points
(0.11%) 39 154 points
(0.41%) 17 790 points
(-0.22%) $80.65
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.20%) $28.93
(3.49%) $1 020.80
(0.28%) $0.936
(0.69%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease...
Stats | |
---|---|
今日成交量 | 8 492 |
平均成交量 | 253 430 |
市值 | 4.50M |
EPS | $-4.58 ( Q1 | 2024-05-15 ) |
下一个收益日期 | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.210 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0190 (0.97%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-23 | Pharmacyte Biotech, Inc. | Sell | 3 854 626 | Series G Convertible Preferred Stock |
2024-05-23 | Pharmacyte Biotech, Inc. | Sell | 3 854 626 | Warrants |
2024-04-08 | Glass Mitchell | Buy | 0 | |
2023-08-24 | Rivard Paul | Buy | 150 000 | Common stock |
2023-08-17 | Rivard Paul | Buy | 25 000 | Common stock |
INSIDER POWER |
---|
-71.04 |
Last 83 transactions |
Buy: 8 607 737 | Sell: 8 242 027 |
MyMD Pharmaceuticals, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.59 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.59 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-11.68 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.850 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
MyMD Pharmaceuticals,
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。